DnB Asset Management
YMAB

DnB Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

DnB Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,399
Closed -$203K – 659
2022
Q2 		$203K Buy
+13,399
New +$156K ﹤0.01% 652
2022
Q1 		– Sell
-13,367
Closed -$217K – 672
2021
Q4 		$217K Buy
13,367
+801
+6% +$17.1K ﹤0.01% 663
2021
Q3 		$359K Sell
12,566
-249
-2% -$7.85K ﹤0.01% 629
2021
Q2 		$433K Buy
+12,815
New +$411K ﹤0.01% 615
2021
Q1 		– Sell
-22,559
Closed -$1.12M – 651
2020
Q4 		$1.12M Buy
+22,559
New +$1.04M 0.01% 558

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

DnB Asset Management's YMAB Position: Q3 2022 in Review

DnB Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2022, closing a stake of 13,399 shares — an estimated $203K sold.

DnB Asset Management first reported a position in YMAB in Q4 2020 and held it in 5 quarters. The position peaked at $1.12M in Q4 2020. 100 funds tracked by Wall St. Rank hold YMAB as of Q3 2022.

  • DnB Asset Management reported no remaining Y-mAbs Therapeutics position as of Q3 2022 after selling out during the quarter.
  • DnB Asset Management sold 13,399 Y-mAbs Therapeutics shares in Q3 2022, an estimated $203K.
  • DnB Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 5 quarters.
  • DnB Asset Management's Y-mAbs Therapeutics position peaked at $1.12M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2022.

Based on DnB Asset Management's 13F filing for Q3 2022, filed 11 Oct 2022.